Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
| |
---|---|
(1) | Registration Statement (Form S-3 No. 333-251858) of Altimmune, Inc., |
(2) | Registration Statement (Form S-8 No. 333-263569) pertaining to 2017 Omnibus Incentive Plan of Altimmune, Inc., |
(3) | Registration Statement (Form S-8 No. 333-248232) pertaining to 2017 Omnibus Incentive Plan of Altimmune, Inc., |
(4) | Registration Statement (Form S-8 No. 333-233273) pertaining to 2017 Omnibus Incentive Plan of Altimmune, Inc., |
(5) | Registration Statement (Form S-8 No. 333-230722) pertaining to 2019 Employee Stock Purchase Plan of Altimmune, Inc., |
(6) | Registration Statement (Form S-8 No. 333-228623) pertaining to 2018 Inducement Grant Plan of Altimmune Inc., |
(7) | Registration Statement (Form S-8 No. 333-217846) pertaining to 2001 Employee Stock Option Plan, 2001 Non-Employee Stock Option Plan, and 2017 Omnibus Incentive Plan of Altimmune, Inc., |
(8) | Registration Statement (Form S-8 No. 333-214765) pertaining to 2007 Long-Term Incentive Compensation Plan of Pharmathene Inc.; and |
(9) | Registration Statement (Form S-8 No. 333-156371) pertaining to 2007 Long-Term Incentive Compensation Plan of Pharmathene Inc. |
of our report dated February 28, 2023, with respect to the consolidated financial statements of Altimmune, Inc., included in this Annual Report (Form 10-K) of Altimmune, Inc. for the year ended December 31, 2022.
|
/s/ Ernst & Young LLP |
|
Tysons, Virginia |
February 28, 2023 |